ArticleScientific reports2025
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biomarker Integration in the Perioperative Management of Early-Stage Non-Small-Cell Lung Cancer.Journal of clinical medicine · 2026Review
- Patterns of central nervous system disease and molecular landscape in epidermal growth factor receptor exon 20 insertion mutated non-small cell carcinoma.Translational lung cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In addition to identifying alterations suitable for molecularly targeted therapy (TT), comprehensive genomic profiling (CGP) may convey prognostic/predictive information in advanced non-small-cell lung cancer (aNSCLC). We investigated the impact of tumor suppressor gene alterations (TSGAs) on aNSCLC patients' outcome in a real-world setting. The IMMINENT clinical-genomic database, which provides data on molecular and clinico-pathological features, treatment history, and patients' outcomes of aNSCLC patients who underwent CGP using tissue- or blood-based next-generation sequencing (NGS) between May 2019 and November 2022 was interrogated to assess overall (OS) and progression-free survival (PFS). The Cox proportional hazard model was used to assess the prognostic and predictive role of genomic features. Two hundred and one patients were included in the analysis. Genomic alterations in STK11, KEAP1, and MYC were associated with poorer OS, while ALK alterations were associated with better OS; after adjustment, STK11 and KEAP1 alterations retained their independent negative prognostic impact. Moreover, KRAS:STK11 and KRAS:KEAP1 co-mutations cooperated to negatively influence OS. In terms of predictive performance, CDKN2A/B alterations predicted worse PFS on chemotherapy (CT) and TP53 alterations predicted worse PFS on TT, while both CDKN2A/B and TP53, as well as KRAS, alterations predicted better PFS on immunotherapy (IO). Extended CGP, encompassing TSGAs, provides valuable prognostic and predictive insights for aNSCLC, thereby adding to the mere identification of potential targets for TT. Our findings also underline the complexity of the lung cancer molecular landscape and suggest the need for studying a personalized therapeutic approach in patients with TSGAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.